SCHEMBL1481100

SCHEMBL1481100

CCn1cc(-c2ccc(Cl)cc2Cl)nc1/C=C/c1ccc(-c2ccc(OCCCCCCC(=O)O)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALB P02768 1/20 0.46
PPARA Q07869 3/20 0.44
FFAR1 O14842 4/20 0.43
PPARG P37231 1/20 0.43
PPARD Q03181 1/20 0.43
FFAR4 Q5NUL3 3/20 0.41
CYSLTR2 Q9NS75 2/20 0.39
CYSLTR1 Q9Y271 2/20 0.39
FABP4 P15090 2/20 0.39
AGER Q15109 1/20 0.39
LTB4R Q15722 3/20 0.38
CNR1 P21554 2/20 0.38
CYP2C9 P11712 1/20 0.38
SCN5A Q14524 1/20 0.38
HDAC3 O15379 1/20 0.36
STAT3 P40763 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1480918 1.00 ALB (0.46) ALBPPARAFFAR1PPARGPPARD
SCHEMBL1480920 1.00 ALB (0.46) ALBPPARAFFAR1PPARGPPARD
SCHEMBL1481103 1.00 ALB (0.46) ALBPPARAFFAR1PPARGPPARD
SCHEMBL1481280 0.99 PPARA (0.44) ALBPPARAFFAR1PPARGPPARD
SCHEMBL1481279 0.99 PPARA (0.44) ALBPPARAFFAR1PPARGPPARD
SCHEMBL1480656 0.97 ALB (0.48) ALBPPARAFFAR1PPARGPPARD
SCHEMBL1480653 0.97 ALB (0.48) ALBPPARAFFAR1PPARGPPARD
SCHEMBL1481594 0.97 FFAR4 (0.44) ALBPPARAFFAR1PPARGPPARD
SCHEMBL1481591 0.97 FFAR4 (0.44) ALBPPARAFFAR1PPARGPPARD
SCHEMBL1481709 0.94 AGER (0.42) ALBPPARAFFAR1FFAR4CYSLTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ ALB 1690/4885PPARA 2236/4885FFAR1 1810/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ ALB 1690/4885PPARA 2236/4885FFAR1 1810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.